BSX vs DXCM — Key Metrics
| Metric | BSX (BOSTON SCIENTIFIC CORP) | DXCM (DEXCOM INC) |
|---|---|---|
| Price | 43.64 | 82.52 |
| Market Cap | 63.26 Billion | 30.78 Billion |
| P/E (TTM) | 18.34 | 31.86 |
| P/B (Quarterly) | 2.506 | 11.758 |
| P/S (TTM) | 3.0 | 6.03 |
| Net Profit Margin (TTM) | 16.6 | 19.4 |
| Gross Margin (TTM) | 69.1 | 63.4 |
| ROE (TTM) | 13.9 | 36.5 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Outperform
Recommendation Summary
Stock BSX is projected to greatly outperform the market, stock DXCM is projected to outperform the market. Upfront Recommendation: BSX.
Financial Metrics
| BSX | Metrics | DXCM |
|---|---|---|
| $43.64 | Price | $82.52 |
| — | Market Capitalization | — |
| 18.34 | Price to Earnings Ratio | 31.86 |
| 3.0 | Price to Sales | 6.03 |
| 18.99 | Price to FCF Ratio | 28.02 |
| 4.34 | Price to Gross Profit | 9.51 |
| 29.3 | Price to R&D | 50.61 |
| 7.75 | Price to Current Assets | 7.86 |
BSX vs DXCM at a glance
Boston Scientific Corp (BSX) and Dexcom INC (DXCM) are both Medical Devices companies in the Healthcare sector. BSX is the larger, at $63.3 billion in market value against $30.8 billion for DXCM, about 2.1 times the size.
On trailing-twelve-month figures, BSX trades at 18.3 times trailing earnings and DXCM at 31.9; net profit margins are 16.6% and 19.4%.
The Upfront Investment model currently rates BSX Greatly Outperform and DXCM Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.